symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
CVKD,0.613,0,80842,7982976,0,0.6-6.75,-0.008,"Cadrenal Therapeutics, Inc. Common Stock",USD,0001937993,,,NASDAQ Global Market,NASDAQ,Biotechnology,https://www.cadrenal.com,"Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.",Mr. Quang X. Pham,Healthcare,US,3,904 300 0701,822 A1A North,Ponte Vedra,FL,32082,,0,https://financialmodelingprep.com/image-stock/CVKD.jpg,2023-01-20,False,False,True,False,False
